Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at email@example.com if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
The highly-anticipated fifth edition is here! Get the must-have resource for achieving compliance with medical device regulations.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
As the European Medicine Agency (EMA) prepares to relocate its headquarters from London, thanks to the Brexit vote, the agency is also restructuring as part of what it says will be a leaner, more streamlined architecture that builds on the overhaul from 2013 and 2014.
The EMA said on Friday that as part of this fine-tuning process, beginning 1 September 2016, the agency will have one less division dealing with human medicines, a newly dedicated focus on strengthening collaborations with member state competent authorities and a further streamlining of its division dealing with administration and corporate planning.
EMA Executive Director Guido Rasi said in a statement: “We want to do more with the resources we have by designing the Agency’s structures and processes around the lifespan of medicines.” He also noted that the fine-tuning is part of progress made over the past two years.
Main changes include:
The EMA also added that interactions between stakeholders and the agency will not be affected by these changes.
Organizational Chart for 1 September 2016
Tags: EMA and Brexit, Brexit, EMA in London